Formulation Development
Croda Expands Biopharma Capabilities Through Strategic Partnership
Croda International Plc recently announced a strategic supply partnership with Amino GmbH aimed at strengthening the global availability of high purity amino acids for pharmaceutical…
Sever Pharma Solutions Appoints Linda Rebert as VP Operations
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in Controlled-Release Drug Delivery Systems for highly potent drugs, with development and manufacturing…
Amphista Therapeutics Announces New AMX-883 Data to be Presented & Provides a Business Progress Update
Amphista Therapeutics recently announced the presentation of new preclinical data with its lead Targeted Glue AMX-883, an orally bioavailable, potent and selective degrader of BRD9…
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics, Inc. recently announced it recently initiated dosing in its BROADEN2 Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of…
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) recently announced the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating…
Sever Pharma Solutions Celebrates 50 years of Pharmaceutical Innovation
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release drug delivery systems for high-potent drugs, is proud to celebrate…
Azalea Therapeutics Presents New Preclinical Data Demonstrating Robust In Vivo Generation of TRAC-CAR T Cells Using Enveloped Delivery Vehicles
Azalea Therapeutics, Inc. recently announced new preclinical data demonstrating robust in vivo generation of functional TRAC-CAR T cells using its proprietary Enveloped Delivery Vehicle (EDV) technology.…
BriaCell & Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
BriaCell Therapeutics Corp. recently announced its subsidiary, BriaPro Therapeutics Corp., has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer…
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
Oncotelic Therapeutics, Inc. recently announced its joint venture partner, GMP Bio, has completed an independent third-party valuation of its drug development pipeline. The preliminary valuation,…
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
FibroBiologics, Inc. recently announced it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial…
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients With Lymphatic Malformations
Protara Therapeutics, Inc. recently announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company’s investigational cell-based therapy,…
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Ltd. recently announced the successful initiation of the Company's Phase 2 clinical study with dosing of the first participant in Canada. The trial…
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics NV recently announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129),…
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
One-carbon Therapeutics AB recently announced the first subject has been successfully dosed in its ODIN Phase 1/2 clinical trial (NCT07151040) evaluating TH9619, a first-in-class MTHFD1/2…
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating…
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Halda Therapeutics recently announced it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in…
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech, Inc. recently provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented…
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension to the FDA
Cereno Scientific, an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, recently announced the submission of…
Nanoform Finland Plc | Inside Information
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it has received a Commercial cGMP Manufacturing License from FIMEA (Finnish…
Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery Through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human…
